On March 25, 2024, the Food and Drug Administration (FDA) approved NeuroStar Advanced Therapy as an adjunct treatment for major depressive disorder (MDD) in patients aged 15 to 21. This makes NeuroStar the first and only transcranial magnetic stimulation (TMS) treatment cleared by the FDA for this age group. The FDA’s decision was based in part on data from NeuroStar’s proprietary TrakStar platform, which examined outcomes for nearly 10,000 adolescents treated with NeuroStar TMS.
